Quest for the right Drug

|
עמוד הבית / ביקטארווי / מידע מעלון לרופא

ביקטארווי BIKTARVY (BICTEGRAVIR AS SODIUM, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AS FUMARATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1   Pharmacodynamic properties

Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations, ATC code: J05AR20

Mechanism of action and pharmacodynamic effects

Bictegravir is an integrase strand transfer inhibitor (INSTI) that binds to the integrase active site and blocks the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Bictegravir has activity against HIV-1 and HIV-2.

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and analogue of 2’-deoxycytidine.
Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate. Emtricitabine triphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse 
transcriptase (RT), which results in DNA chain-termination. Emtricitabine has activity against HIV-1, HIV-2 and HBV.

Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonamidate prodrug of tenofovir (2’-deoxyadenosine monophosphate analogue). Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil in loading tenofovir into peripheral blood mononuclear cells (PBMCs) (including lymphocytes and other HIV target cells) and macrophages. Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain- termination. Tenofovir has activity against HIV-1, HIV-2 and HBV.

Antiviral activity in vitro

The antiviral activity of bictegravir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4+ T-lymphocytes.
The 50% effective concentration (EC50) values for bictegravir were in the range of < 0.05 to 6.6 nM.
The protein-adjusted EC95 of bictegravir was 361 nM (0.162 µg/mL) for wild type HIV-1 virus.
Bictegravir displayed antiviral activity in cell culture against HIV-1 group (M, N, O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from < 0.05 to 1.71 nM), and activity against HIV-2 (EC50 = 1.1 nM).

The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs. The EC50 values for emtricitabine were in the range of 0.0013 to 0.64 µM. Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 µM) and showed activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 µM).

The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4+ T-lymphocytes. The EC50 values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including subtypes A, B, C, D, E, F, and G (EC50 values ranged from 0.10 to 12.0 nM) and activity against HIV-2 (EC50 values ranged from 0.91 to 2.63 nM).

Resistance

In vitro
HIV-1 isolates with reduced susceptibility to bictegravir have been selected in cell culture. In one selection, amino acid substitutions M50I and R263K emerged and phenotypic susceptibility to bictegravir was reduced 1.3-, 2.2-, and 2.9-fold for M50I, R263K, and M50I + R263K, respectively.
In a second selection, amino acid substitutions T66I and S153F emerged and phenotypic susceptibility to bictegravir was shifted 0.4-, 1.9-, and 0.5-fold for T66I, S153F, and T66I + S153F, respectively.

HIV-1 isolates with reduced susceptibility to emtricitabine have been selected in cell culture and had M184V/I mutations in HIV-1 RT.

HIV-1 isolates with reduced susceptibility to tenofovir alafenamide have been selected in cell culture and had the K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed. HIV-1 isolates with the K65R mutation have low level reduced susceptibility to abacavir, emtricitabine, tenofovir, and lamivudine. In vitro drug resistance selection studies with tenofovir alafenamide have shown no development of high-level resistance after extended culture.

In vivo
In treatment-naïve patients (Studies GS-US-380-1489 and GS-US-380-1490), through Week 144 of the double-blind phase or 96 weeks of the open-label extension phase, no patient receiving Biktarvy, 
with HIV-1 RNA ≥ 200 copies/mL at the time of confirmed virologic failure or early study drug discontinuation, had HIV-1 with treatment-emergent genotypic or phenotypic resistance to bictegravir, emtricitabine, or tenofovir alafenamide in the final resistance analysis population (n = 11 with data).
At the time of study entry, one treatment-naïve patient had pre-existing INSTI resistance-associated mutations Q148H + G140S and had HIV-1 RNA < 50 copies/mL at Week 4 through Week 144. In addition, 6 patients had the pre-existing INSTI resistance-associated mutation T97A; all had HIV-1 RNA < 50 copies/mL at Week 144 or the last visit.

In virologically-suppressed patients (Studies GS-US-380-1844 and GS-US-380-1878), no patients receiving Biktarvy, with HIV-1 RNA ≥ 200 copies/mL at the time of confirmed virologic failure, Week 48, or early study drug discontinuation, had HIV-1 with treatment-emergent genotypic or phenotypic resistance to bictegravir, emtricitabine, or tenofovir alafenamide in the final resistance analysis population (n = 2).

Cross-resistance
The susceptibility of bictegravir was tested against 64 INSTI-resistant clinical isolates (20 with single substitutions and 44 with 2 or more substitutions). Of these, all single and double mutant isolates lacking Q148H/K/R and 10 of 24 isolates with Q148H/K/R with additional INSTI resistance associated substitutions had ≤ 2.5-fold reduced susceptibility to bictegravir; > 2.5-fold reduced susceptibility to bictegravir was found for 14 of the 24 isolates that contained G140A/C/S and Q148H/R/K substitutions in integrase. Of those, 9 of the 14 isolates had additional mutations at L74M, T97A, or E138A/K. In a separate study, site-directed mutants with G118R and T97A+G118R had 3.4- and 2.8-fold reduced susceptibility to bictegravir, respectively. The relevance of these in vitro cross-resistance data remains to be established in clinical practice.

Bictegravir demonstrated equivalent antiviral activity against 5 nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, 3 NRTI-resistant, and 4 protease inhibitor (PI)-resistant HIV-1 mutant clones compared with the wild-type strain.

Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.
The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine. Multinucleoside resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.

Clinical data

The efficacy and safety of Biktarvy in HIV-1 infected, treatment-naïve adults are based on 48-week and 144-week data from two randomised, double-blind, active-controlled studies, GS-US-380-1489 (n = 629) and GS-US-380-1490 (n = 645). Furthermore, additional efficacy and safety data are available from adults who received open-label Biktarvy for an additional 96 weeks after Week 144 in an optional extension phase of these studies (n = 1025).

The efficacy and safety of Biktarvy in virologically-suppressed HIV-1 infected adults are based on 48- week data from a randomised, double-blind, active-controlled study, GS-US-380-1844 (n = 563); and a randomised, open-label, active-controlled study, GS-US-380-1878 (n = 577).

HIV-1 infected, treatment-naïve patients
In Study GS-US-380-1489, patients were randomised in a 1:1 ratio to receive either bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (n = 314) or abacavir/dolutegravir/lamivudine (600/50/300 mg) (n = 315) once daily. In Study GS-US-380-1490, patients were randomised in a 1:1 ratio to receive either B/F/TAF (n = 320) or dolutegravir + emtricitabine/tenofovir alafenamide (50+200/25 mg) (n = 325) once daily.

In Studies GS-US-380-1489 and GS-US-380-1490, the mean age was 35 years (range 18-77), 89% were male, 58% were White, 33% were Black, and 3% were Asian. Twenty-four percent (24%) of 
patients identified as Hispanic/Latino. The prevalence of different subtypes was comparable across all three treatment groups, with subtype B predominant in both groups; 11% were non-B subtypes. The mean baseline plasma HIV-1 RNA was 4.4 log10 copies/mL (range 1.3-6.6). The mean baseline CD4+ cell count was 460 cells/mm3 (range 0-1,636) and 11% had CD4+ cell counts less than 200 cells/mm3.
Eighteen percent of patients had baseline viral loads greater than 100,000 copies/mL. In both studies, patients were stratified by baseline HIV-1 RNA (less than or equal to 100,000 copies/mL, greater than 100,000 copies/mL to less than or equal to 400,000 copies/mL, or greater than 400,000 copies/mL), by CD4+ cell count (less than 50 cells/μL, 50-199 cells/μL, or greater than or equal to 200 cells/μL), and by region (US or ex-US).

Treatment outcomes of Studies GS-US-380-1489 and GS-US-380-1490 through Weeks 48 and 144 are presented in Table 3.

Table 3: Pooled virologic outcomes of Studies GS-US-380-1489 and GS-US-380-1490 at Weeks 48a and 144b

Week 48                                     Week 144
ABC/DTG/         DTG +         B/F/TAF       ABC/DTG         DTG +
B/F/TAF
3TC           F/TAF         (n = 634)c      /3TC          F/TAF
(n = 634)c
(n = 315)d      (n = 325)e                   (n = 315)d     (n = 325)e HIV-1 RNA                       91%           93%             93%           82%            84%            84% < 50 copies/mL
Treatment difference           -           -2.1%          -1.9%                        -2.7%          -1.9% (95% CI) B/F/TAF vs                      (-5.9% to      (-5.6% to          -         (-7.8% to      (-7.0% to Comparator                                 1.6%)          1.8%)                        2.4%)          3.1%) HIV-1 RNA                        3%            3%             1%             3%            3%             3% ≥ 50 copies/mLf
No virologic data at             6%            4%             6%            16%            13%             13% week 48 or 144 window
Discontinued study           <1%            1%             1%             2%             2%             3% drug due to AE or deathg
Discontinued study            4%            3%             4%            13%            11%             9% drug due to other reasons and last available HIV-1
RNA
< 50 copies/mLh
Missing data during           2%            <1%            1%             1%            ≤1%             1% window but on study drug
Proportion (%) of patients with
HIV-1 RNA
< 50 copies/mL by subgroup
By baseline viral load
≤ 100,000 copies/mL          92%            94%            93%           82%            86%             84% > 100,000 copies/mL          87%            90%            94%           79%            74%             83% By baseline CD4+ cell count                           90%            81%           100%           80%            69%             91% < 200 cells/mm3              91%            94%            92%           82%            86%             83% ≥ 200 cells/mm3
HIV-1 RNA                       85%            87%            87%           78%            82%             79% < 20 copies/mL
ABC = abacavir      DTG = dolutegravir 3TC = lamivudine       F/TAF = emtricitabine/tenofovir alafenamide a     Week 48 window was between Day 295 and 378 (inclusive).
b     Week 144 window was between Day 967 and 1050 (inclusive).
c     Pooled from Study GS-US-380-1489 (n=314) and Study GS-US-380-1490 (n = 320).
d     Study GS-US-380-1489.
e     Study GS-US-380-1490.


f     Includes patients who had ≥ 50 copies/mL in the Week 48 or 144 window; patients who discontinued early due to lack or loss of efficacy (n = 0); patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy (B/F/TAF n = 12 and 15; ABC/DTG/3TC n = 2 and 7; DTG+F/TAF n = 3 and 6, at Weeks 48 and 144, respectively) and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
g     Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
h     Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g. withdrew consent, loss to follow-up, etc.

B/F/TAF was non-inferior in achieving HIV-1 RNA < 50 copies/mL at both Weeks 48 and 144 when compared to abacavir/dolutegravir/lamivudine and to dolutegravir + emtricitabine/tenofovir alafenamide, respectively. Treatment outcomes between treatment groups were similar across subgroups by age, sex, race, baseline viral load, baseline CD4+ cell count, and region.

In Studies GS-US-380-1489 and GS-US-380-1490, the mean increase from baseline in CD4+ cell count at Week 144 was 288, 317, and 289 cells/mm3 in the pooled B/F/TAF, abacavir/dolutegravir/lamivudine, and dolutegravir + emtricitabine/tenofovir alafenamide groups, respectively.

In the optional 96 week open-label extension phase of Studies GS-US-380-1489 and GS-US-380-1490, high rates of virologic suppression were achieved and maintained.

HIV-1 infected, virologically-suppressed patients
In Study GS-US-380-1844, the efficacy and safety of switching from a regimen of dolutegravir + abacavir/lamivudine or abacavir/dolutegravir/lamivudine to B/F/TAF were evaluated in a randomised, double-blind study of virologically-suppressed (HIV-1 RNA < 50 copies/mL) HIV-1 infected adults (n=563). Patients must have been stably suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 3 months prior to study entry. Patients were randomised in a 1:1 ratio to either switch to B/F/TAF at baseline (n = 282), or stay on their baseline antiretroviral regimen (n=281).
Patients had a mean age of 45 years (range 20-71), 89% were male, 73% were White, and 22% were Black. Seventeen percent (17%) of patients identified as Hispanic/Latino. The prevalence of different HIV-1 subtypes was comparable between treatment groups, with subtype B predominant in both groups; 5% were non-B subtypes. The mean baseline CD4+ cell count was 723 cells/mm3 (range 124-2,444).

In Study GS-US-380-1878, the efficacy and safety of switching from either abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate (200/300 mg) plus atazanavir or darunavir (boosted by either cobicistat or ritonavir) to B/F/TAF were evaluated in a randomised, open-label study of virologically-suppressed HIV-1 infected adults (n = 577). Patients must have been stably suppressed on their baseline regimen for at least 6 months and must not have been previously treated with any INSTI. Patients were randomised in a 1:1 ratio to either switch to B/F/TAF (n = 290), or stay on their baseline antiretroviral regimen (n = 287). Patients had a mean age of 46 years (range 20-79), 83% were male, 66% were White, and 26% were Black. Nineteen percent (19%) of patients identified as Hispanic/Latino. The mean baseline CD4+ cell count was 663 cells/mm3 (range 62-2,582). The prevalence of different subtypes was comparable across treatment groups, with subtype B predominant in both groups; 11% were non-B subtypes. Patients were stratified by prior treatment regimen. At screening, 15% of patients were receiving abacavir/lamivudine plus atazanavir or darunavir (boosted by either cobicistat or ritonavir) and 85% of patients were receiving emtricitabine/tenofovir disoproxil fumarate plus atazanavir or darunavir (boosted by either cobicistat or ritonavir).

Treatment outcomes of Studies GS-US-380-1844 and GS-US-380-1878 through Week 48 are presented in Table 4.



Table 4: Virologic outcomes of Studies GS-US-380-1844 and GS-US-380-1878 at Week 48a 
Study GS-US-380-1844                     Study GS-US-380-1878
Baseline ATV-
B/F/TAF(n =         ABC/DTG/3TC             B/F/TAF       or DRV-based 282)              (n = 281)             (n = 290)        regimen
(n = 287)
HIV-1 RNA < 50 copies/mL                         94%                95%                   92%               89% Treatment difference (95% CI)                   -1.4% (-5.5% to 2.6%)                    3.2% (-1.6% to 8.2%) HIV-1 RNA ≥ 50 copies/mLb                         1%                <1%                    2%                2% Treatment difference (95% CI)                   0.7% (-1.0% to 2.8%)                     0.0% (-2.5% to 2.5%) No virologic data at Week 48
5%                   5%                  6%                  9% window
Discontinued study drug due to
AE or death and last available                 2%                   1%                  1%                  1% HIV-1 RNA < 50 copies/mL
Discontinued study drug due to other reasons and last available               2%                   3%                  3%                  7% HIV-1 RNA < 50 copies/mLc
Missing data during window but
2%                   1%                  2%                  2% on study drug
ABC = abacavir         ATV = atazanavir       DRV = darunavir         DTG = dolutegravir 3TC = lamivudine a     Week 48 window was between Day 295 and 378 (inclusive).
b     Includes patients who had ≥ 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
c     Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g. withdrew consent, loss to follow-up, etc.

B/F/TAF was non-inferior to the control regimen in both studies. Treatment outcomes between treatment groups were similar across subgroups by age, sex, race, and region.

In GS-US-380-1844, the mean change from baseline in CD4+ cell count at Week 48 was -31 cells/mm3 in patients who switched to B/F/TAF and 4 cells/mm3 in patients who stayed on abacavir/dolutegravir/lamivudine. In GS-US-380-1878, the mean change from baseline in CD4+ cell count at Week 48 was 25 cells/mm3 in patients who switched to B/F/TAF and 0 cells/mm3 in patients who stayed on their baseline regimen.

Patients co-infected with HIV and HBV
The number of patients co-infected with HIV and HBV treated with B/F/TAF is limited. In Study GS-US-380-1490, 8 patients with HIV/HBV co-infection at baseline were randomised to receive B/F/TAF. At Week 48, 7 patients were HBV suppressed (HBV DNA < 29 IU/mL) and had HIV-1 RNA < 50 copies/mL. One patient had missing HBV DNA data at Week 48. At Week 144, 5 patients were HBV suppressed and had HIV-1 RNA < 50 copies/mL. Three patients had missing HBV DNA data at Week 144 (1 lost to follow-up from Week 48, 1 lost to follow-up after Week 72, and 1 lost to follow-up after Week 120).

In Study GS-US-380-1878, at Week 48, 100% (8/8) of the patients co-infected with HIV/HBV at baseline in the B/F/TAF arm maintained HBV DNA < 29 IU/mL (missing = excluded analysis) and HIV RNA < 50 copies/mL.

Pharmacokinetic Properties

5.2    Pharmacokinetic properties

Absorption
Bictegravir is absorbed following oral administration with peak plasma concentrations occurring at 2.0-4.0 hours after administration of B/F/TAF. Relative to fasting conditions, the administration of
B/F/TAF with either a moderate fat (~600 kcal, 27% fat) or high fat meal (~800 kcal, 50% fat) 

resulted in an increase in bictegravir AUC (24%). This modest change is not considered clinically meaningful and B/F/TAF can be administered with or without food.

Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple dose mean (CV%) pharmacokinetic parameters of bictegravir were Cmax = 6.15 µg/mL (22.9%), AUCtau = 102 µg•h/mL (26.9%), and Ctrough = 2.61 µg/mL (35.2%).

Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1.5-2.0 hours after administration of B/F/TAF. The mean absolute bioavailability of emtricitabine from 200 mg hard capsules was 93%. Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food and B/F/TAF can be administered with or without food.

Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple dose mean (CV%) pharmacokinetic parameters of emtricitabine were Cmax = 2.13 µg/mL (34.7%), AUCtau = 12.3 µg•h/mL (29.2%), and Ctrough = 0.096 µg/mL (37.4%).

Tenofovir alafenamide is rapidly absorbed following oral administration with peak plasma concentrations occurring at 0.5-2.0 hours after administration of B/F/TAF. Relative to fasting conditions, the administration of tenofovir alafenamide with a moderate fat meal (~600 kcal, 27% fat) and a high fat meal (~800 kcal, 50% fat) resulted in an increase in AUClast by 48% and 63%, respectively. These modest changes are not considered clinically meaningful and B/F/TAF can be administered with or without food.

Following oral administration of B/F/TAF with or without food in HIV-1 infected adults, the multiple dose mean (CV%) pharmacokinetic parameters of tenofovir alafenamide were Cmax = 0.121 µg/mL (15.4%), and AUCtau = 0.142 µg•h/mL (17.3%).

Distribution

In vitro binding of bictegravir to human plasma proteins was > 99% (free fraction ~0.25%). The in vitro human blood to plasma bictegravir concentration ratio was 0.64.

In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02 to 200 µg/mL. At peak plasma concentration, the mean plasma to blood emtricitabine concentration ratio was ~1.0 and the mean semen to plasma emtricitabine concentration ratio was ~4.0.

In vitro binding of tenofovir to human plasma proteins is ≤ 0.7% and is independent of concentration over the range of 0.01-25 µg/mL. Ex-vivo binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%.

Biotransformation

Metabolism is the major clearance pathway for bictegravir in humans. In vitro phenotyping studies showed that bictegravir is primarily metabolised by CYP3A and UGT1A1. Following a single dose oral administration of [14C]-bictegravir, ~60% of the dose from faeces included unchanged parent, desfluoro-hydroxy-BIC-cysteine-conjugate, and other minor oxidative metabolites. Thirty-five percent of the dose was recovered from urine and consisted primarily of the glucuronide of bictegravir and other minor oxidative metabolites and their phase II conjugates. Renal clearance of the unchanged parent was minimal.

Following administration of [14C]-emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~86%) and faeces (~14%). Thirteen percent of the dose was recovered in the urine as three putative metabolites. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3’-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2’-O-glucuronide (~4% of dose). No other metabolites were identifiable.

Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80% of an oral dose. In vitro studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes. In vivo, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite, tenofovir diphosphate. In human clinical studies, a 25 mg oral dose of tenofovir alafenamide resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil.

Elimination

Bictegravir is primarily eliminated by hepatic metabolism. Renal excretion of intact bictegravir is a minor pathway (~1% of dose). The plasma bictegravir half-life was 17.3 hours.

Emtricitabine is primarily excreted by the kidneys by both glomerular filtration and active tubular secretion. The plasma emtricitabine half-life was approximately 10 hours.

Tenofovir alafenamide is eliminated following metabolism to tenofovir. Tenofovir alafenamide and tenofovir have a median plasma half-life of 0.51 and 32.37 hours, respectively. Tenofovir is eliminated by the kidneys by both glomerular filtration and active tubular secretion. Renal excretion of intact tenofovir alafenamide is a minor pathway with less than 1% of the dose eliminated in urine.

Linearity

The multiple dose pharmacokinetics of bictegravir are dose proportional over the dose range of 25 to 100 mg. The multiple dose pharmacokinetics of emtricitabine are dose proportional over the dose range of 25 to 200 mg. Tenofovir alafenamide exposures are dose proportional over the dose range of 8 mg to 125 mg.

Other special populations

Hepatic impairment
Clinically relevant changes in the pharmacokinetics of bictegravir were not observed in subjects with moderate hepatic impairment. The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited. Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild, moderate, or severe hepatic impairment.

Renal impairment
Severe Renal Impairment (estimated creatinine clearance ≥ 15 and < 30 mL/minute) No clinically relevant differences in bictegravir, tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and subjects with severe renal impairment (estimated CrCl ≥ 15 mL/min and < 30 mL/min) in Phase 1 Studies. In a separate Phase 1 study of emtricitabine alone,mean systemic emtricitabine exposure was higher in patients with severe renal impairment (CrCl < 30 mL/min) (33.7 µg•h/mL) than in subjects with normal renal function (11.8 µg•h/mL). The safety of Biktarvy has not been established in subjects with estimated creatinine clearance ≥ 15 mL/min and < 30 mL/min.

End Stage Renal Disease (estimated creatinine clearance < 15 mL/minute) Exposures of emtricitabine and tenofovir in 12 patients with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis who received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed dose combination tablet in Study GS-US-292- 1825 were significantly higher than in patients with normal renal function. No clinically relevant differences in tenofovir alafenamide pharmacokinetics were observed in patients with end stage renal disease on chronic haemodialysis as compared to those with normal renal function. In the extension 
phase of Study GS-US-292-1825, lower bictegravir Ctrough was observed in patients with end stage renal disease who received Biktarvy compared to patients with normal renal function, but this difference was not considered clinically relevant. No additional adverse reactions were identified in patients with end stage renal disease on chronic haemodialysis in this study (see section 4.8).

There are no pharmacokinetic data on bictegravir, emtricitabine or tenofovir alafenamide in patients with end stage renal disease (estimated CrCl < 15 mL/min) not on chronic haemodialysis. The safety of Biktarvy has not been established in these patients.

Age, gender and race
Pharmacokinetics of bictegravir, emtricitabine, and tenofovir have not been fully evaluated in the elderly (≥ 65 years of age). Population analyses using pooled pharmacokinetic data from adult studies did not identify any clinically relevant differences due to age, gender or race on the exposures of bictegravir, emtricitabine, or tenofovir alafenamide.

Table 5: Exposures of Bictegravir, Emtricitabine, Tenofovir Alafenamide and Tenofovir in Adults

Adultsa

B/F/TAF (50 mg/200 mg/25 mg) n = 77
BIC
AUCtau                                                  94 227.1 (34.7) (ng•h/mL)
Cmax                                                    6 801.6 (30.1) (ng/mL)
Ctau                                                    2 256.7 (47.3)b (ng/mL)
FTC
AUCtau                                                  12 293.6 (29.2) (ng•h/mL)
Cmax                                                    2 127.0 (34.7) (ng/mL)
Ctau                                                      96.0 (37.4)c (ng/mL)
TAF
AUCtau                                                   229.3 (63.0) (ng•h/mL)
Cmax                                                     276.5 (62.4) (ng/mL)
Ctau                                                         N/A
(ng/mL)
TFV
AUCtau                                                   292.6 (27.4)d (ng•h/mL)
Cmax                                                      15.2 (26.1)d (ng/mL)
Ctau                                                      10.6 (28.5)d (ng/mL)
BIC = bictegravir; FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable; %CV = percentage coefficient of variation
Data are presented as mean (%CV).
a Intensive PK data from Studies GS-US-380-1489, GS-US-380-1490, GS-US-380-1844, GS-US-380-1878 for BIC, FTC and TAF PK exposures and population PK data from Studies GS-US-292-0104 and GS-US-292-0111 for TFV PK exposures b n = 75 c n = 74 d n = 841



פרטי מסגרת הכללה בסל

א. התרופה האמורה תינתן לטיפול בנשאי HIV.ב. מתן התרופה ייעשה לפי מרשם של מנהל מרפאה לטיפול באיידס, במוסד רפואי שהמנהל הכיר בו כמרכז AIDS.ג. משטר הטיפול בתרופה יהיה כפוף להנחיות המנהל, כפי שיעודכנו מזמן לזמן על פי המידע העדכני בתחום הטיפול במחלה.

מסגרת הכללה בסל

התוויות הכלולות במסגרת הסל

התוויה תאריך הכללה תחום קליני Class Effect מצב מחלה
טיפול בנשאי HIV 16/01/2019 מחלות זיהומיות HIV
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 16/01/2019
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

GILEAD SCIENCES ISRAEL LTD

רישום

161 87 35648 01

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

15.08.22 - עלון לרופא 27.09.23 - עלון לרופא

עלון מידע לצרכן

21.02.22 - עלון לצרכן אנגלית 21.02.22 - עלון לצרכן עברית 03.03.21 - עלון לצרכן ערבית 21.02.22 - עלון לצרכן ערבית 27.09.23 - עלון לצרכן אנגלית 27.09.23 - עלון לצרכן עברית 11.10.23 - עלון לצרכן ערבית 28.04.19 - החמרה לעלון 30.07.19 - החמרה לעלון 14.11.19 - החמרה לעלון 02.08.20 - החמרה לעלון 02.09.21 - החמרה לעלון 20.12.21 - החמרה לעלון 21.02.22 - החמרה לעלון 15.08.22 - החמרה לעלון 27.09.23 - החמרה לעלון

לתרופה במאגר משרד הבריאות

ביקטארווי

קישורים נוספים

RxList WebMD Drugs.com